Oct 5 (Reuters) - Sanofi SA:
* Appellate Court orders a new trial and vacates permanent injunction in ongoing patent case regarding Praluent® (alirocumab)
* Sanofi - co and Regeneron do not anticipate any new trial proceedings to start in 2017
* Sanofi says U.S. Court of Appeals ruling means that co, Regeneron will continue marketing, selling, manufacturing Praluent (alirocumab) injection in U.S
* Sanofi - Court has ordered new trial, vacated permanent injunction in dispute concerning Amgen’s asserted patent claims for antibodies targeting PCSK9 Source text for Eikon: Further company coverage: